pre-IPO PHARMA

COMPANY OVERVIEW

Bioniz Therapeutics is an emerging biopharmaceutical company leading the discovery and development of first-in-class peptide therapeutics that selectively and simultaneously inhibit multiple cytokines to treat immuno-inflammatory diseases and cancer.


LOCATION

  • Irvine, CA, USA

  • THERAPEUTIC AREAS

  • Autoimmune Disease
  • Inflammatory DIsease
  • Oncology

  • WEBSITE

    https://bioniz.com/


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Feb 16, 2022

    Equillium Acquires Bioniz Therapeutics Significantly Expanding Pipeline of Novel Immunomodulatory Drug Candidates


    Nov 9, 2021

    Bioniz Therapeutics to Present at Evercore ISI 4th Annual HealthCONx Conference


    May 12, 2021

    Bioniz Therapeutics Expands Board of Directors and Leadership Team as Company Advances Lead Drug Candidate in Late-Stage Clinical Trials


    Apr 6, 2021

    Bioniz Therapeutics Receives Orphan Drug Designation from the European Commission for BNZ-1 for Treatment of Cutaneous T-Cell Lymphoma


    Mar 24, 2021

    Bioniz Therapeutics Appoints Dr. Alexandre Kaoukhov to Leadership Team


    For More Press Releases


    Google Analytics Alternative